A nurse is planning to administer epoetin alfa subcutaneously to a client who has anemia. Which of the following actions should the nurse take?
Monitor the client for hypotension.
Inject at a 15-degree angle.
Check the client’s hemoglobin level.
Administer the medication in the deltoid.
The Correct Answer is C
A. Monitor the client for hypotension is not specifically required for epoetin alfa administration. Hypotension is not a common adverse effect of this medication.
B. Inject at a 15-degree angle is incorrect. Subcutaneous injections are typically administered at a 45 to 90-degree angle, not 15 degrees.
C. Check the client’s hemoglobin level is essential before administering epoetin alfa. Epoetin alfa stimulates red blood cell production, and monitoring hemoglobin levels helps assess the effectiveness and safety of the treatment.
D. Administer the medication in the deltoid is not the preferred site for subcutaneous injections. Epoetin alfa is usually administered in the abdomen or thigh.
Nursing Test Bank
Naxlex Comprehensive Predictor Exams
Related Questions
Correct Answer is D
Explanation
A. Temperature is not the primary assessment needed before administering propranolol. While it is important to monitor vital signs, temperature does not directly impact the administration of propranolol.
B. Respiratory rate is important to monitor, but it is not the primary assessment needed before administering propranolol. Propranolol primarily affects the cardiovascular system.
C. Pain level is not directly related to the administration of propranolol. While pain management is important, it does not influence the decision to administer propranolol.
D. Heart rate is the primary assessment needed before administering propranolol. Propranolol can cause bradycardia (slow heart rate), so it is crucial to check the client’s heart rate before administration. If the heart rate is below 60 beats per minute, the medication should be withheld, and the provider should be notified.
Correct Answer is B
Explanation
A. Digoxin and levothyroxine. These medications do not typically interact to cause hearing loss. Digoxin is used for heart conditions, and levothyroxine is a thyroid hormone replacement. Their interaction does not pose a risk for ototoxicity.
B. Furosemide and amikacin. This combination is known to cause ototoxicity. Furosemide is a loop diuretic, and amikacin is an aminoglycoside antibiotic. Both drugs have ototoxic potential, and their combined use increases the risk of hearing loss.
C. Losartan and atorvastatin. These medications do not typically interact to cause hearing loss. Losartan is an antihypertensive, and atorvastatin is a cholesterol-lowering agent. Their interaction does not pose a risk for ototoxicity.
D. Propranolol and raloxifene. These medications do not typically interact to cause hearing loss. Propranolol is a beta-blocker, and raloxifene is used for osteoporosis. Their interaction does not pose a risk for ototoxicity.
Whether you are a student looking to ace your exams or a practicing nurse seeking to enhance your expertise , our nursing education contents will empower you with the confidence and competence to make a difference in the lives of patients and become a respected leader in the healthcare field.
Visit Naxlex, invest in your future and unlock endless possibilities with our unparalleled nursing education contents today
Report Wrong Answer on the Current Question
Do you disagree with the answer? If yes, what is your expected answer? Explain.
Kindly be descriptive with the issue you are facing.